Results 61 to 70 of about 1,154,986 (294)

How is Nanoarchitectonics Shaping Extracellular Vesicle Research?

Advanced Healthcare Materials, EarlyView.
The convergence of nanoarchitectonics and extracellular vesicle biology is reshaping next‐generation nanomedicine by enabling rationally designed nanostructures for enhanced EVs detection, engineering, and therapy. ABSTRACT Extracellular vesicles (EVs) have gained recognition as crucial mediators of cell‐to‐cell communication, holding immense potential
Madushani Dahanayake, Md Shahriar A. Hossain, Chia‐Hung Liu, Carlos Salomon, Yusuke Yamauchi, Mostafa Kamal Masud   +5 more
wiley   +1 more source

From Cell‐Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery

Advanced Healthcare Materials, EarlyView.
Biologically derived and hybrid nonviral nanovectors are examined as distinct but convergent design approaches. Integrating synthetic components with biologically functionalized membranes allows efficient interactions with complex cellular environments.
Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano, Ilaria Elena Palamà   +10 more
wiley   +1 more source

Development of Phage Lysin LysA2 for Use in Improved Purity Assays for Live Biotherapeutic Products

Viruses, 2015
Live biotherapeutic products (LBPs), commonly referred to as probiotics, are typically preparations of live bacteria, such as Lactobacillus and Bifidobacterium species that are considered normal human commensals.
Sheila M. Dreher-Lesnick, Jeremy E. Schreier, Scott Stibitz   +2 more
doaj   +1 more source

A Chemical Framework for Engineering Extracellular Vesicles’ Biointerface to Advance Precision Therapeutics

Advanced Materials, EarlyView.
Extracellular vesicles (EVs) are cell‐derived nanoparticles that mediate intercellular communication through their dynamic biointerfaces. Owing to their intrinsic biological functions, EVs have emerged as promising platforms for biomedical applications.
Leila Pourtalebi Jahromi, Felix Geng, Jan‐Noël Frenzke, Gregor Fuhrmann   +3 more
wiley   +1 more source

Serotyping and Cross-Reactivity’s Between Different Pseudomonas aeruginosa Isolates Prevalent in Iran

Iranian Journal of Microbiology, 2010
Background and Objectives: 300 Pseudomonas aeruginosa strains were isolated from hospitalized patients in Iran. Using international antigenic typing system (IATS) antibodies, all strains were classified into 16 serotypes while serotype 14 was not ...
H Ahmadi, S Malekian, B Tabaraie, D Norouzian, F Poormirza-gholi, M Nejati, MH Hedayati, MR Beik Mohammadi, A Behnoodi, M Izadpanahi   +9 more
doaj  

Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States

BMC Infectious Diseases, 2023
Background Invasive extraintestinal pathogenic Escherichia coli disease (IED) can lead to severe outcomes, particularly among older adults. However, the clinical burden of IED in the U.S. has not been well characterized.
Luis Hernandez-Pastor, Jeroen Geurtsen, Bryan Baugh, Antoine C. El Khoury, Nnanya Kalu, Marjolaine Gauthier-Loiselle, Rebecca Bungay, Martin Cloutier, Michal Sarnecki, Elie Saade   +9 more
doaj   +1 more source

Vaccines against human enteric bacterial pathogens

, 2002
The development of vaccines against enteric bacterial pathogens presents a challenge because of the large number of pathogens capable of causing disease and the requirement to induce immunity that is effective in the gut.
Huett, Alan, Dougan, Gordon, Clare, Simon   +2 more
core   +1 more source

Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation [PDF]

, 2011
Natural fluctuations in carried meningococcal genotypes and phenotypes a can be affected by the use of conjugate vaccines, and not all of these changes are anticipatable in advance of vaccine ...
McCarthy, Noel D., Maclennan, Jenny, Evans, Meirion R, Rachel Urwin, Cameron, J. Claire, Neal, Keith R, Ibarz-Pavón, AB, Nicholas J. Andrews, Stuart C. Clarke, Cann, Kathryn, Maiden, MC, Noel D. McCarthy, Cameron, JC, Evans, MR, Maiden, Martin, James M. Stuart, Harrison, S, Ala'aldeen, Dlawer, Cunningham, Richard, Martin C. J. Maiden, Jolley, Keith A, Derrick W. Crook, Dlawer Ala'Aldeen, Walker, AM, Baxter, David, Gray, Stephen J., Urwin, R, Crook, Derrick W., Keith R. Neal, Clarke, SC, Clarke, Stuart C, Maiden, Martin C. J., Jolley, Keith A., Stuart, James M., Maiden, Martin CJ, Maclennan, J, Keith A. Jolley, Kaczmarski, E, Walker, A. Mark, J. Simon Kroll, Richard Cunningham, Andrews, NJ, J. Claire Cameron, Crook, DW, Evans, Meirion Rhys, Harrison, Sarah, Andrews, Nicholas J, Ala'aldeen, D, Edward Kaczmarski, Baxter, D, McCarthy, Noel D, Cann, K, Crook, Derrick W, Kathryn Cann, Ibarz-Pavón, Ana Belén, Clarke, Stuart C., Evans, Meirion R., A. Mark Walker, Cunningham, R, Kroll, J. Simon, Kroll, J Simon, Neal, KR, Cameron, J Claire, Maiden, MCJ, Andrews, Nicholas J., Neal, Keith R., McCarthy, ND, Stephen J. Gray, Jenny MacLennan, Meirion R. Evans, Crook, Derrick, Urwin, Rachel, Stuart, James M, Stuart, JM, Sarah Harrison, Gray, SJ, Gray, Stephen J, Ana Belén Ibarz-Pavón, Walker, A Mark, Kaczmarski, Edward, David Baxter, Andrews, Nicholas J., Kroll, JS, Jolley, KA   +83 more
core   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Cysteine Redox State Governs the Condensation Pathway of Hendra Virus W Protein and Differentially Impacts Type I IFN and NF‐κB Signaling

Advanced Science, EarlyView.
The cysteine redox state of the Hendra virus W (WHeV) protein controls assembly into fibrils or amorphous aggregates, with residues 2–29 required for fibrillation. In cells, WHeV forms different types of nuclear condensates. Impaired ability to form redox‐sensitive, non‐filamentous condensates reduces WHeV inhibition of the NF‐κB pathway, while it ...
Frank Gondelaud, Alexandre Lalande, Giulia Pesce, Auriane Bouchet, Carole Meunier, Christophe Bignon, Denis Ptchelkine, Yu Gu, Eva Ogire, Pierre‐Yves Lozach, Denis Gerlier, Cyrille Mathieu, Sonia Longhi   +12 more
wiley   +1 more source